{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-253747","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2024-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.473747+00:00","generated_at":"2026-05-30T02:54:53.396002+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"AlloVir to merge with Kalaris in all-stock deal; Kalaris stockholders to own ~75% of combined company","bullets":["AlloVir acquires Kalaris; pre-merger AlloVir stockholders own ~25.05%, Kalaris ~74.95% on fully diluted basis, subject to net cash adjustments.","Combined company expected to have ~$100M cash at close (expected Q1 2025), providing runway into Q4 2026.","Pipeline focuses on TH103 (anti-VEGF fusion protein) for neovascular AMD; Phase 1 data expected Q3 2025; also planned for DME and RVO.","Stockholders owning 87.4% of Kalaris and 29.4% of AlloVir have entered support agreements to vote in favor.","Post-close company to rename Kalaris Therapeutics, trade on Nasdaq under ticker KLRS."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-253747","json":"https://secwatch.observer/filing/0001193125-24-253747.json","markdown":"https://secwatch.observer/filing/0001193125-24-253747.md","text":"https://secwatch.observer/filing/0001193125-24-253747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/0001193125-24-253747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312524253747/d870301d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T02:54:53.396002+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}